Palbociclib and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is reported as a side effect among people who take Palbociclib (palbociclib), especially for people who are female, 60+ old, also take Zoledronic Acid, and have Breast cancer.

The phase IV clinical study analyzes which people have Poor venous access when taking Palbociclib. It is created by eHealthMe based on reports of 11,617 people who have side effects when taking Palbociclib from the FDA, and is updated regularly.

What is Palbociclib?

Palbociclib has active ingredients of palbociclib. eHealthMe is studying from 11,622 Palbociclib users. Check the latest studies of Palbociclib.

What is Poor venous access?

Poor venous access is found to be associated with 676 drugs and 480 conditions by eHealthMe. Check the latest studies of Poor venous access.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

11,617 people reported to have side effects when taking Palbociclib.
Among them, 16 people (0.14%) have Poor venous access.

Could Palbociclib cause Poor venous access?

Among these 16 people:

What is the gender of people who have Poor venous access when taking Palbociclib? *

female: 100 %
male: 0.0 %

What is the age of people who have Poor venous access when taking Palbociclib? *

What are other drugs people take besides Palbociclib? *

What are other side effects people have besides Poor venous access? *

Thrombocytopenia (decrease of platelets in blood): 15 people, 93.75%
Pain: 15 people, 93.75%
Anaemia (lack of blood): 15 people, 93.75%
Carbohydrate Antigen 15-3 Increased: 15 people, 93.75%
Constipation: 15 people, 93.75%
Dehydration (dryness resulting from the removal of water): 15 people, 93.75%
Fatigue (feeling of tiredness): 15 people, 93.75%
Nausea (feeling of having an urge to vomit): 15 people, 93.75%
Blood Creatinine Increased: 14 people, 87.50%
Metastases To Lung (cancer spreads to lung): 12 people, 75.00%

What are the existing conditions these people have? *

Breast Cancer: 10 people, 62.50%
Metastases To Bone (cancer spreads to bone): 9 people, 56.25%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 6.25%
Breast Cancer Metastatic: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Palbociclib and have Poor venous access?

- Check whether Poor venous access is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Palbociclib:

Palbociclib (11,622 reports)

Browse all side effects of Palbociclib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Poor venous access:

Poor venous access (676 drugs)

Browse all the conditions that are associated with Poor venous access:

Poor venous access (480 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Palbociclib) and Palbociclib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.